GW Pharmaceuticals (LON: GWP) is to launch its Sativex therapy for multiple sclerosis sufferers in Denmark later this month after the country recently approved the medicine.
GW Pharma, and its Spanish partner Almirall, reported that Denmark’s Interior and Health Minister had approved Sativex – which will be the first cannabis-based medicine in Denmark after a change to Danish laws.
The news comes just days after the company announced it would be launching Sativex in Germany this July after that county’s health authorities also approved the treatment.
Sativex is a first-in-class ‘endocannabinoid’ (cannabis-based) system modulator for the treatment of spasticity in MS. It is delivered by a spray that can be delivered into the mouth either onto the inside of the cheek or under the tongue.
Spasticity (also known as muscle stiffness) has a negative impact on patients’ daily lives as it reduces their capacity to carry out everyday activities such as walking and keeping upright, as well as having an impact on their general mobility, bladder function and quality of sleep.
According to GW Pharma, around half of people with MS do not manage to find relief from these symptoms with currently-available treatments.
The firm says that evidence generated from clinical trials shows that Sativex has a positive impact on spasticity in MS, while alleviating associated symptoms.
In addition to the launch of Sativex in Germany and Denmark, GW Pharma expects to launch the treatment in Sweden by the end of this year and in Italy, the Czech Republic and Austria in 2012.
At 11:11am this morning, GW Pharma’s shares were down a penny at 120 pence each.